Clozapine and COVID-19: The authors respond (Letter)
File version
Author(s)
Honer, WG
Clark, S
Correll, CU
Hasan, A
Howes, O
Kane, JM
Kelly, DL
Laitman, R
Lee, J
MacCabe, JH
Myles, N
Nielsen, J
Wheeler, A
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
We compliment the authors and journal for ensuring the “Consensus statement on the use of clozapine during the COVID-19 pandemic” was published in a timely fashion. Coronavirus disease 2019 (COVID-19) rapidly transformed into a pandemic, challenging medicine in ways initially not imagined; this is certainly the case not only for treatmentresistant schizophrenia and for reasons related to clozapine, but also the patient population.
Journal Title
Journal of Psychiatry and Neuroscience
Conference Title
Book Title
Edition
Volume
45
Issue
4
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Neurosciences
Cognitive and computational psychology
Persistent link to this record
Citation
Siskind, D; Honer, WG; Clark, S; Correll, CU; Hasan, A; Howes, O; Kane, JM; Kelly, DL; Laitman, R; Lee, J; MacCabe, JH; Myles, N; Nielsen, J; Schulte, PF; Taylor, D; Verdoux, H; Wheeler, A; Freudenreich, O, Clozapine and COVID-19: The authors respond (Letter), Journal of Psychiatry and Neuroscience, 2020, 45 (4), pp. E1-E2